New skin scanner could reveal hidden changes in eczema treatment

NCT ID NCT07568665

Recruiting now Knowledge-focused Sponsor: Hôpitaux Drôme Nord Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special microscope (reflectance confocal microscopy) can detect skin changes in people with moderate-to-severe eczema who are taking tralokinumab. The drug blocks a protein involved in inflammation and is already known to help eczema. Researchers want to see if the microscope can measure skin thickness and structure more precisely than standard exams. Only 15 adults are being enrolled, and the focus is on imaging, not on whether the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tralokinumab
What this could lead to: If successful, this could show that a non-invasive skin scan can track treatment effects, potentially improving how doctors monitor eczema therapy.
What could go wrong: This is a very small, early-stage study (15 people) focused on imaging, not on proving the drug works. Results may not apply to everyone with eczema.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS (AD) ATOPIC DERMATITIS ECZEMA

Contacts and locations

Locations

Hopitaux Drome NOrd
RECRUITING

Romans-sur-Isère, Drôme, 26100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.